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S U M M A R Y
Objective: To describe the outcomes of antiretroviral therapy (ART) in a large cohort of HIV-infected
children in Thailand.
Methods: The data were obtained from four collaborative referral sites around the country. Data from
2008 to March 2011 were collected prospectively, and data before 2008 were collected retrospectively.
Results: Of the 1139 children, 599 (52.6%) were female, and the duration of ART was a median 2.9 years
(interquartile range (IQR) 3.3–5.5 years). At ART initiation, the median age was 7.1 years (IQR 3.4–10.0
years), CD4 percentage was 9.0% (IQR 3.0–17.0%), and 61.3% were in World Health Organization (WHO)
stage 3 or 4. Seventy-four percent were initiated on an NNRTI-based regimen. The death and lost to
follow-up rates were 1.3 (95% conﬁdence interval (CI) 1.1–1.6) and 2.2 (95% CI 1.6–2.6)/100 patient-
years of follow-up, respectively. At the last clinic visit of 919 children, the median CD4 percentage was
27.0% (IQR 23.0–32.0%) and 80.2% had HIV-RNA <40 copies/ml. WHO stage 1 or 2 at ART initiation was
associated with having a viral load <40 copies/ml (p < 0.002), and baseline CD4 15% and starting with a
three-drug regimen were associated with achieving CD4 25% (p < 0.001).
Conclusions: Although most children initiated ART at low CD4 levels, the majority achieved immune
reconstitution and long-term virological control. Earlier treatment may improve these outcomes.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious
Diseases. 
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The introduction of highly active antiretroviral therapy
(HAART) has improved the outcomes of HIV-infected children
and adolescents.1–5 A long-term follow-up study among perina-
tally HIV-infected children and adolescents showed that the use of* Corresponding author.
E-mail address: sikch@mahidol.ac.th (K. Chokephaibulkit).
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http://dx.doi.org/10.1016/j.ijid.2013.12.011HAART reduced mortality from 7.2 to 0.8/100 person-years
between 1994 and 2000, and this remained relatively stable
through 2006.1,2 Studies of antiretroviral therapy (ART) outcomes
in resource-limited settings have also shown encouraging clinical
outcomes.3,4,6–8 A study in the Democratic Republic of the Congo
demonstrated that HAART reduced the mortality risk in HIV-
infected children by 75%.3 Changes in the causes of death in HIV-
infected children and adolescents have also been observed during
the HAART era. Deaths due to opportunistic infections have
declined, but non-AIDS-deﬁning infections and multi-organ failure
have become the major causes of mortality.2
In resource-limited settings, there continues to be a major gap
in coverage of ART for children compared to adults. It is estimatedociety for Infectious Diseases. Open access under CC BY-NC-ND license.
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of adult counterparts.9 Furthermore, available information on the
long-term outcomes of treatment in children in low- and middle-
income countries is limited. The ‘Pediatric Progress’ database was
set up to systematically collect clinical data from four major
referral sites in Thailand. As Thailand has been facing the HIV
epidemic longer than other Asian countries, and the National
Program providing ART has been established since the year 2000,
this database affords a unique opportunity to study long-term
treatment outcomes in children.
2. Materials and methods
We conducted a pooled analysis of data from the pediatric HIV-
infected cohort in the Pediatric Progress database, from four
collaborative referral sites in Thailand, including two sites in
Bangkok (Siriraj Hospital and The HIV Netherlands Australia
Thailand Research Collaboration (HIV-NAT)) and two sites in
northern Thailand (Chiangrai Prachanukroh Hospital and Sanpatong
Hospital). The inclusion criteria were HIV-infected children andTable 1
Demographic characteristics of 1139 HIV-infected children at ART initiation
Characteristics <18 months
(n = 179)
18–5
(n = 2
Site 
Siriraj Hospital 136 (76) 88 (
HIV-NAT 21 (11.7) 53 (
Chiangrai Prachanukroh Hospital 21 (11.7) 61 (
Sanpatong Hospital 1 (0.6) 3 (
Gender 
Female 85 (47.5) 103 (
Age at ARV initiation, median (IQR) years 0.6 (0.4–1) 3.3
Mode of transmission 
Mother to child transmission 174 (97.2) 200 (
Blood transfusion 0 (0) 0 (
Sexual transmission 0 (0) 0 (
Sexual abuse 0 (0) 0 (
Breast feeding 1 (0.6) 1 (
Unknown 4 (2.2) 4 (
WHO stage at ARV initiation 
Stage 1 12 (6.7) 12 (
Stage 2 21 (11.7) 32 (
Stage 3 40 (22.4) 63 (
Stage 4 36 (20.1) 42 (
Unavailable data 70 (39.1) 56 (
Initial ARV regimen 
Mono/dual NRTIs 111 (62) 62 (
Triple NRTIs 1 (0.6) 1 (
NNRTI-based HAART 37 (20.7) 133 (
PI-based HAART 29 (16.2) 7 (
Other 1 (0.6) 2 (
ARV regimen at last clinic visit (n = 919) 
Mono/dual NRTIs 5 (4.1) 8 (
NNRTI-based HAART 48 (39.7) 95 (
PI-based HAART 41 (33.9) 39 (
Double-boosted PIs 1 (0.8) 1 (
Triple classes 8 (6.6) 3 (
Third-line regimensa 8 (6.6) 7 (
Other 10 (8.3) 11 (
Duration of ARV therapy, median (IQR) years 5.6 (2.2–11.1) 6.6
Cause of death 
HIV-related 3 (30) 3 (
Non-HIV-related 2 (20) 1 (
Unknown 5 (50) 1 (
ART, antiretroviral therapy; ARV, antiretroviral; HAART, highly active antiretroviral thera
NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; WHO, World H
a Third-line regimens included darunavir, maraviroc, and etravirine-based regimens. F
11 of these were initially treated with mono or dual NRTI. Two children were participat
with mono or dual NRTI and after developing resistance had switched to single or double
dyslipidaemia. The median duration of ART treatment in these 27 children was 9 yearadolescents <18 years of age at study entry who had initiated ART.
HIV-infected children and adolescents who were older than 18 years
of age at study entry and those who had not initiated ART, or who had
an uncertain ART regimen or start date, were excluded. All sites are
able to access HIV RNA and CD4 testing. Children were followed
clinically every 3 months. CD4 counts and percentages were
monitored every 6 months and HIV RNA viral loads (VL) every 12
months. Treatment followed the national guidelines, with the use of
non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
HAART as the preferred ﬁrst-line regimen; ART was fully available
at no cost to the patient, supported by the Ministry of Public Health.
Data were collected prospectively from 2008 until March 2011. Data
from before 2008 were retrieved retrospectively from the medical
records, back to ART initiation, which was ﬁrst started in 1996.
Baseline CD4 and VL were collected at ART initiation. Baseline CD4
counts and percentages were the measurements closest to ART
initiation, as long as this was between 180 days prior to and 14 days
after ART initiation. Baseline VL was considered to be the result taken
closest to the initiation of ART, within a period of 365 days before and
14 days after ART initiation. The ﬁrst ART regimen used was9 months
05)
60 months
(n = 755)
Overall
(n = 1139)
p-Value
<0.001
42.9) 130 (17.2) 354 (31.1)
25.9) 136 (18) 210 (18.4)
29.8) 454 (60.1) 536 (47.1)
1.5) 35 (4.6) 39 (3.4)
0.187
50.2) 411 (54.4) 599 (52.6)
 (2.3–4.2) 9.1 (7.2–11.1) 7.1 (3.4–10.0) <0.0001
0.587
97.6) 727 (96.3) 1101 (96.7)
0) 4 (0.5) 4 (0.4)
0) 3 (0.4) 3 (0.3)
0) 1 (0.1) 1 (0.1)
0.5) 0 (0) 2 (0.2)
2) 20 (2.6) 28 (2.5)
<0.001
5.9) 86 (11.4) 110 (9.7)
15.6) 176 (23.3) 229 (20.1)
30.7) 161 (21.3) 264 (23.2)
20.5) 197 (26.1) 275 (24.1)
27.3) 135 (17.9) 261 (22.9)
<0.001
30.2) 59 (7.8) 232 (20.4)
0.5) 3 (0.4) 5 (0.4)
64.9) 674 (89.3) 844 (74.1)
3.4) 11 (1.5) 47 (4.1)
1) 8 (1.1) 11 (1)
<0.001
4.9) 11 (1.7) 24 (2.6)
57.9) 473 (74.6) 616 (67)
23.8) 98 (15.5) 178 (19.4)
0.6) 8 (1.3) 10 (1.1)
1.8) 5 (0.8) 16 (1.7)
4.3) 12 (1.9) 27 (2.9)
6.7) 27 (4.3) 48 (5.2)
 (3.6–8.8) 5.2 (2.9–7.1) 5.5 (2.9–7.6) <0.0001
0.002
60) 56 (84) 62 (76)
20) 6 (9) 9 (11)
20) 5 (7) 11 (13)
py; IQR, interquartile range; NNRTI, non-nucleoside reverse transcriptase inhibitor;
ealth Organization.
ifteen of 27 children were on third-line regimens because of virological failure, and
ing in clinical trials using these agents. The remaining 10 children had been treated
-boosted PI regimens. These children were switched to darunavir because of severe
s (IQR 5–12 years).
Table 2
Primary cause of death in 82 HIV-infected children (total 85 causes of death)a
Cause of death n (%)
End-stage AIDSb 22 (25.9)
AIDS-deﬁning infection/conditionc 17 (20.0)
Pneumocystis jirovecii pneumonia (PCP) 6 (7.1)
Mycobacterium avium complex 1 (1.2)
Cryptococcal meningitis 3 (3.5)
Penicilliosis 3 (3.5)
Cerebral toxoplasmosis 2 (2.4)
HIV encephalopathy 1 (1.2)
Progressive multifocal leukoencephalopathy 1 (1.2)
Mycobacterium tuberculosis infection 8 (9.4)
Pneumonia 9 (10.6)
Bacterial sepsis 3 (3.5)
Diarrhea 2 (2.4)
Lactic acidosis 1 (1.2)
Cardiomyopathy 1 (1.2)
Serious adverse events from ART 2 (2.4)
Non-AIDS events 9 (10.6)
Accident/drowning 3 (3.5)
Head injury 2 (2.4)
Cardiovascular disease 2 (2.4)
Suicide 1 (1.2)
Aspiration 1 (1.2)
Unknown 11 (12.9)
ART, antiretroviral therapy; CDC, US Centers for Disease Control and Prevention.
a One child died from pneumonia and diarrhea, one died from sepsis and
cardiomyopathy, and one from disseminated penicilliosis and progressive
multifocal leukoencephalopathy.
b Children who died from ‘end-stage AIDS’ were deﬁned as children who died in
the advanced stage of HIV infection from organ failure or unidentiﬁed infections, or
when no other cause could be identiﬁed.
c We deﬁned ‘AIDS-deﬁning illness’ according to the 1993 deﬁnition of CDC
clinical category C. We also included disseminated Penicillium marneffei infection.
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30 days. The last clinic visit results were the most recent results
within 365 days before March 31, 2011. A child was considered lost
to follow-up (LTFU) if there was no contact and no data available
after March 31, 2010.
Data management and the statistical analysis were conducted
with SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and Stata
version 11 (StataCorp, College Station, TX, USA). Logistic regression
was used to identify factors associated with a VL <40 copies/ml
and CD4 25% at the last clinic visit. Variables with a p-value of
<0.15 in the univariate analysis were adjusted for in the
multivariate models.Table 3
Comparison of clinical characteristics of HIV-infected children at ART initiation and las
Clinical characteristics At ARV initiation
(n = 1139)
CD4 (No. of children with available data)a (869) 
CD4%, median (IQR) 9 (3–17)a
CD4 cell count (cells/mm3), median (IQR) 192 (40–553)a
CD4 25%, n (%) 91 (10.5) 
Viral load (No. of children with available data)a (316) 
Viral load (copies/ml), median (IQR) 114 111 (39 900
Log10 viral load, median (IQR) 5.1 (4.6–5.6) 
Viral load <40 copies/ml, n (%) 11 (3.5) 
Weight-for-age Z-score, median (IQR) 1.8 (2.6 to 0
Height-for-age Z-score, median (IQR) 1.8 (2.9 to 0
WHO stage, n (%) 
Stage 1 110 (9.7) 
Stage 2 229 (20.1) 
Stage 3 264 (23.2) 
Stage 4 275 (24.1) 
Data unavailable 261 (22.9) 
ART, antiretroviral therapy; ARV, antiretroviral; IQR, interquartile range; WHO, World 
a Baseline CD4 and viral load were collected closest to the date of ARV initiation (CD4 w
ART initiation).3. Results
Of 1228 children enrolled in the cohort, 89 were excluded; 72
had not initiated ART and 17 had uncertain ART regimens and start
dates. Sixty-ﬁve percent of cases were cared for at the sites in
Bangkok, in Central Thailand. Of the 1139 included in the analysis,
599 (52.5%) were female, 96.7% had acquired HIV perinatally, and
the median age at start of ART was 7.1 years (interquartile range
(IQR) 3.4–10.0 years) (Table 1). One-hundred and forty (12.3%)
children were younger than 12 months of age at ART initiation. The
median CD4 percentage at ART initiation (data available for 869
children) was 9.0% (IQR 3.0–17.0%). Of 316 children who had
baseline HIV RNA measured, median HIV RNA was 5.1 log10 copies/
ml (IQR 4.6–5.6 log10 copies/ml). Of the 878 children with available
baseline World Health Organization (WHO) clinical staging
recorded, 539 (61.3%) were moderately to severely symptomatic
(WHO stage 3 or 4). The majority (74.1%) of the initial regimens
were NNRTI-based. However, 232 (20.4%) children in this cohort
were started on mono or dual nucleoside reverse transcriptase
inhibitor (NRTI)-based regimens.
The median duration of follow-up was 2.9 years (IQR 3.3–5.5
years). During 6281 patient-years of follow-up (PYFU) there were
82 deaths, and 138 children were lost to follow-up, giving death
and lost to follow-up rates of 1.3 (95% CI 1.1–1.6) and 2.2 (95% CI
1.6–2.6)/100 PYFU, respectively. The median age of children at the
time of death was 9.4 years (IQR 6.8–11.6 years). The median
duration from ART initiation to death was 0.5 years (IQR 0.1–1.4
years). Forty-ﬁve (54.9%) children died within 6 months after ART
initiation. Causes of death were identiﬁed in 71 (86.6%) children;
78.0% were from HIV-related conditions (Table 2). The most
common cause of death was end-stage AIDS (31.7%), followed by
pneumonia (11.0%), Mycobacterium tuberculosis infection (9.8%),
and Pneumocystis jirovecii pneumonia (PCP) (7.3%). In the children
who died of end-stage AIDS, the median CD4 percentage was 1%
(IQR 1–4.5%), and the majority (73%) had WHO disease stage 4
when ART was initiated.
There were 919 children under active follow-up for a median
duration of 6.4 years (IQR 4.1–7.9 years). Of these, 616 (67.0%)
were still on NNRTI-based HAART, 193 (21.0%) were on second-line
protease inhibitor (PI)-based HAART, and 22 children (2.4%) were
on third-line regimens at their last clinic visit. The median
increases in CD4 count and percentage from baseline were 352.2
(95% CI 311.6–392.8) cells/mm3 and 10.4% (95% CI 9.8–11.1%),
respectively, at 1 year of ART. The median CD4 count, percentage,t clinic visit
At last clinic visit
(n = 919)
p-Value
(890) <0.0001
27 (23–32)
722 (527–934)
575 (64.6)
(804) <0.0001
–409 190) 40 (40–40)
1.6 (1.6–1.6)
645 (80.2)
.8) 1.0 (1.7 to 0.05) <0.0001
.8) 1.1 (2.0 to 0.3) <0.0001
<0.0001
30 (3.3)
260 (28.3)
351 (27.3)
254 (27.6)
124 (13.5)
Health Organization.
ithin 180 days before and 14 days after, VL within 365 days before and 14 days after
Table 4
Factors associated with viral load <40 copies/ml at the last clinic visit
Variables Univariate analysis Multivariate analysis
OR (95% CI) p-Value OR (95% CI) p-Value
Female 1.11 (0.95–1.32) 0.38 - -
Age at ARV initiation 0.04 0.40
<18 months Ref. Ref.
18–59 months 1.63 (1.08–2.44) 2.67 (0.73–9.79)
60–155 months 1.57 (1.13–2.19) 2.22 (0.63–7.81)
>155 months 1.21 (0.69–2.1) 1.32 (0.31–5.56)
Infant ARV exposure for PMTCT 0.98 (0.64–1.52) 0.946 - -
WHO stage 0.05 0.002
Stage 1, 2 Ref. Ref.
Stage 3, 4 0.77 (0.58–1.01) 0.33 (0.17–0.66)
Initial ARV regimen 0.01 0.49
NNRTI-based HAART Ref. Ref.
PI-based HAART 0.61 (0.34–1.09) 1.65 (0.39–7.06)
Other 0.69 (0.52–0.91) 0.66 (0.21–2.05)
Log viral load at baseline 0.19 - -
<3 Ref.
3–3.99 2.1 (0.53–8.37)
4–4.99 1.21 (0.4–3.69)
>5 2.08 (0.75–5.78)
CD4 percentage at baseline <15% 1.1 (0.41–0.77) 0.51 - -
Weight-for-age Z-score <1.5 0.56 (0.41–0.77) <0.001 1.24 (0.57–2.71) 0.59
Height-for-age Z-score <1.5 0.64 (0.47–0.87) 0.01 0.71 (0.32–1.56) 0.39
ARV, antiretroviral; CI, conﬁdence interval; HAART, highly active antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; OR, odds ratio; PI, protease
inhibitor; PMTCT, prevention of mother to child transmission; WHO, World Health Organization.
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signiﬁcantly from baseline (Table 3). At the last clinic visit, the
median CD4 count and percentage were 722 cells/mm3 (IQR 527–
934 cells/mm3) and 27% (IQR 23–32%), respectively, and 80.2% had
HIV-RNA <40 copies/ml.
In the univariate analysis, factors associated with a VL <40
copies/ml at the last clinic visit were age 18 months, baseline
WHO stage 1 or 2, initial ART regimen other than NNRTI-based, and
baseline weight-for-age and height-for-age Z-scores 1.5.
However, on multivariate analysis, only baseline WHO clinical
stage 1 or 2 was independently associated with a VL <40 copies/ml
at the last clinic visit (Table 4). Factors identiﬁed by univariate
analysis to be associated with CD4 25% included age 18 months,
WHO stage 1 or 2, use of NNRTI- or PI-based HAART, and baseline
CD4 percentage 15%. In the multivariate analysis, baseline CD4
15% and using an NNRTI- or PI-based regimen at initiation,
compared to regimens including mono, dual, triple NRTIs, andTable 5
Factors associated with CD4 25% at the last clinic visit
Variables Univariate 
OR (95% CI) 
Female 1.12 (0.95–1.32) 
Age at ARV initiation 
<18 months Ref. 
18–59 months 1.32 (1.00–1.76) 
60–155 months 2.17 (1.68–2.79) 
>155 months 4.87 (3.06–7.75) 
Infant ARV exposure for PMTCT 1.08 (0.82–1.41) 
WHO stage 
Stage 1, 2 Ref. 
Stage 3, 4 0.77 (0.64–0.93) 
Initial ARV regimen 
NNRTI-based HAART 11.32 (8.03–15.96) 
PI-based HAART 18.23 (11.24–29.57) 
Other Ref. 
CD4 percentage at baseline 15% 1.2 (0.98–1.47) 
Weight-for-age Z-score <1.5 0.9 (0.72–1.11) 
Height-for-age Z-score <1.5 0.95 (0.77–1.19) 
ARV, antiretroviral; CI, conﬁdence interval; HAART, highly active antiretroviral therapy;
inhibitor; PMTCT, prevention of mother to child transmission; WHO, World Health Orothers, were signiﬁcantly associated with reaching CD4 25% at
the last clinic visit (Table 5).
4. Discussion
The ‘Pediatric Progress’ database was developed to provide
longitudinal clinical data of HIV-infected children receiving care in
large referral centers under the Thai National Treatment Program.
More than 90% of children in the cohort were receiving ART. The
majority (61.3%) of those with available data initiated ART when
they were in WHO clinical stage 3 or 4 and had a low CD4 level
(median 9%, 192 cells/mm3). After a median 6.4 years of follow-up,
80.2% of HIV-infected children had a VL <40 copies/ml and 64.6%
had CD4 recovery to 25%. We found that the initiation of ART in
children with WHO stage 1 or 2 (vs. stage 3 or 4) was more likely to
lead to good virological control, and children who initiated ART
when CD4 15% and started on either NNRTI- or PI-based HAART,Multivariate
p-Value OR (95% CI) p-Value
0.16 - -
<0.01 0.11
Ref.
0.97 (0.65–1.44)
1.05 (0.72–1.53)
1.93 (1.08–3.46)
0.59 - -
0.01 0.13
Ref.
0.85 (0.68–1.05)
<0.01 <0.0001
13.01 (7.53–22.5)
17.35 (9.23–32.62)
Ref.
0.08 1.71 (1.33–2.21) <0.001
0.32 - -
0.67 - -
 NNRTI, non-nucleoside reverse transcriptase inhibitor; OR, odds ratio; PI, protease
ganization.
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and others, were more likely to achieve normal CD4. The mortality
rate was low at 1.3/100 PYFU.
A report from the TREAT Asia Pediatric HIV Observational
Database (TApHOD) collected from 14 sites in six countries in the
Asia-Paciﬁc region, including Cambodia, Indonesia, Malaysia,
India, Vietnam, and Thailand, demonstrated that 81% of HIV-
infected children who started ART, mostly NNRTI-based HAART,
achieved a VL <400 copies/ml at 36 months of follow-up.6,7,10
Children who were females (hazard ratio (HR) 1.4, 95% CI 1.2–1.7),
started on ART before 18 months of age (HR 3.8, 95% CI 2.4–6.2),
were never treated with mono/dual-therapy (HR 1.7, 95% CI 1.4–
2.5), and with a higher baseline CD4 (per 10% increase: HR 2.0, 95%
CI 1.9–2.2) were more likely to reach CD4 25% within 5 years.6 A
recent study on long-term survival of 578 HIV-infected Thai
children receiving ART at 40 public hospitals under the Programs
for HIV Prevention and Treatment (PHPT) cohort, demonstrated
that a low CD4 percentage and low weight-for-height Z-score at
ART initiation were independently associated with mortality
(p < 0.001).11 A study on outcomes of ART in 13 611 children in
Asia and Africa, a comparative analysis of the IeDEA pediatric
multiregional collaboration, demonstrated that younger age (<24
months), WHO stage 4, and CD4 <10% were among independent
factors associated with poorer survival.12 All of these studies,
together with the results of our study, suggest that early treatment
with HAART is the principal factor for a good outcome.
The PACTG 219/219C study of a pediatric HIV cohort in the USA
also demonstrated that HAART initiation increased the CD4 cell
percentage by 2.3% (95% CI 1.3–3.3%) in the ﬁrst year. Although
larger increases in the CD4 cell percentage were observed among
children with a severe degree of immunosuppression at baseline,
the mean CD4 cell percentage after 5 years of HAART did not reach
normal levels in these children.1 Our study found a higher increase
in CD4 percentage of 10% after the ﬁrst year, and children with
baseline CD4 15% had a higher chance of having CD4 >25% at the
last visit (HR 1.7).
TApHOD reported an overall mortality rate in Asian countries of
2.1/100 person-years among those who were on combination ART.6,7
A report from the Democratic Republic of the Congo during the
HAART era demonstrated a mortality rate of 3.2 deaths/100 person-
years among HIV-infected children on HAART.3 The mortality rate in
this report was lower even than the TApHOD report, and comparable
to the PACTG 219/219C cohort in the USA, where the majority were
treated with PI-based HAART and demonstrated a mortality of 1.47
deaths/100 person-years.2 This is a marker of success of the national
ART program implemented in routine care.
The majority (78%) of deaths in our cohort were the result of
HIV-related conditions and occurred in children who had entered
the treatment program with advanced disease. End-stage AIDS and
infections, particularly pneumonia, tuberculosis, and PCP,
remained major causes of death in spite of ART, mostly occurring
within the ﬁrst 6 months of ART initiation. These results are similar
to a report from a pediatric HIV cohort in Cambodia, in which
tuberculosis and lower respiratory tract infections were the most
common contributing illnesses to death among those who were
and were not on ART.13 The causes of death among HIV-infected
children in high-income countries have changed. Data from the
PACTG 219/219C cohort demonstrated that deaths due to
opportunistic infections have declined in the HAART era, but
non-AIDS-deﬁning infections and multi-organ failure remain
major causes of mortality in HIV-1-infected children.2
The number of children requiring third-line ART is increasing
worldwide. We found that by March 2011, 2.4% of children in our
cohort were on third-line ART, including darunavir, maraviroc, and
etravirine-based regimens. The HIV-NAT 113 study of 1910
children on ART at eight sites in Thailand revealed that 492(26%) were on lopinavir/ritonavir (LPV/r)-based second-line
therapy and 30 (1.5%) were on or waiting for third-line ART.14
These data are alarming, as the availability of and access to salvage
ART regimens is limited in developing regions.
There are certain limitations to be considered with our study.
Children lost to follow-up, who made up to 12.1% of the children in
our cohort, may have been unreported deaths, resulting in an
underestimation of mortality. On the other hand, the four sites that
provided care for children in this cohort are referral centers, thus
more children with advanced HIV disease were enrolled. This may
have led to an overestimation of mortality. Furthermore, some data
were collected retrospectively, resulting in incomplete informa-
tion. Strengths of this study are that it represents the real world in
routine care, with a large sample size and a considerably long
duration of follow-up (almost 3 years). In addition, universal
coverage of HIV treatment has been provided by the Thai National
Health Security Ofﬁce since 2007 and practical aspects of the
program have been standardized in both adults and children with
HIV. Ongoing quality assurance programs are conducted to ensure
consistency of care. For this reason, we believe our study results are
representative of children with HIV in Thailand.
In conclusion, although most Thai children in this cohort
initiated ART when they had advanced HIV infections, the
mortality rate was low – comparable to or better than other
studies in Asia and comparable to high-income countries.
Furthermore, long-term outcomes demonstrated close-to-normal
CD4 and the majority achieved virological control. End-stage AIDS
and HIV-related infections remained the major causes of death.
Earlier access to HIV care and HAART may lead to better outcomes.
It is expected that the outcomes and mortality observed in our
study will continue to improve over time, as the National
Antiretroviral Treatment Program has been implemented longer
and all the HIV-infected infants/children are detected earlier. Long-
term follow-up of the children in this cohort is necessary.
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